Narrowing the field: cancer-specific promoters for mitochondrially-targeted p53-BH3 fusion gene therapy in ovarian cancer
Abstract Background Despite years of research, the treatment options and mortality rate for ovarian cancer remain relatively stagnant. Resistance to chemotherapy and high heterogeneity in mutations contribute to ovarian cancer’s lethality, including many mutations in tumor suppressor p53. Though wil...
Main Authors: | Katherine Redd Bowman, Ji Hoon Kim, Carol S. Lim |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-04-01
|
Series: | Journal of Ovarian Research |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13048-019-0514-4 |
Similar Items
-
Modulation of Telomerase Activity in Cancer Cells by Dietary Compounds: A Review
by: Takahiro Eitsuka, et al.
Published: (2018-02-01) -
The Challenges and Prospects of p53-Based Therapies in Ovarian Cancer
by: Bryce Wallis, et al.
Published: (2023-01-01) -
Ovarian Telomerase and Female Fertility
by: Simon Toupance, et al.
Published: (2021-07-01) -
Anti-Cancer Immunotherapies Targeting Telomerase
by: Simone Negrini, et al.
Published: (2020-08-01) -
The Role of Natural Flavonoids as Telomerase Inhibitors in Suppressing Cancer Growth
by: Neel Parekh, et al.
Published: (2023-04-01)